Bristol Myers Squibb  announced its participation in the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress. The company will present data from over 130 studies, highlighting advancements in oncology and hematology across approximately 25 cancer types and serious blood disorders.

"At this year’s ASCO and EHA meetings, we have the opportunity to share data across our robust and differentiated oncology portfolio including new data from pivotal studies, data that reinforce the longer-term impact our medicines are having for patients, and emerging science in the oncology space," said Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Drug Development, Bristol Myers Squibb. "We are focused on advancing critical research across immuno-oncology, targeted therapy, protein degradation, cell therapy, and radiopharmaceutical therapy, all with the goal of delivering potentially transformative treatment options that help provide long-term benefit for patients."

Key highlights of data being presented by Bristol Myers Squibb include:

New Pivotal Data:

• Progression-free survival and overall response rate data from the Phase 3 KRYSTAL-12 study evaluating KRAZATI® (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
• First disclosure of results from the Phase 3 CheckMate -9DW trial demonstrating overall survival benefit with Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. investigator’s choice of lenvatinib or sorafenib as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC).

Data Strengthening the Profile of Existing Portfolio:

• Three-year follow-up data from the Phase 3 RELATIVITY-047 study demonstrating sustained responses with Opdualag™ (nivolumab and relatlimab-rmbw) in previously untreated metastatic or unresectable melanoma.
• Five-year data from the Phase 3 CheckMate -9LA trial showing favorable clinical outcomes and durable survival benefit in patients with metastatic NSCLC treated with Opdivo plus Yervoy with chemotherapy vs. chemotherapy.

Emerging Science:

• Efficacy and safety data from the Phase 2/3 RELATIVITY-048 trial evaluating the triplet combination of nivolumab, relatlimab, and ipilimumab in patients with advanced melanoma.
• Safety and efficacy data from the Phase 1b portion of the ACTION-1 trial of RYZ101 (an alpha-emitting radiopharmaceutical in development for SSTR2+ solid tumors) in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy.

These presentations underscore Bristol Myers Squibb's commitment to advancing innovative therapies that address the unmet needs of patients with cancer and serious blood disorders.